Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail industry is undergoing an evolution in the "people, goods, and scene" framework, driven by emotional consumption, which presents new opportunities for growth [3][25] - High-end gold and fashion jewelry are gaining traction among consumers, with a focus on product differentiation and cultural significance [3][32] - The cosmetics industry is innovating through the IP of technical ingredients and cultural confidence, enhancing product appeal and market competitiveness [3][37] - Offline retail is shifting from selling "goods" to offering "services and experiences," with companies like Yonghui Supermarket leading the transformation [3][41] Summary by Sections Retail Market Overview - In 2025, the retail sector index closed at 2422.59 points, with an annual increase of 8.21%, underperforming the Shanghai Composite Index, which rose by 18.41% [5][14] - The retail industry ranked 23rd among 31 sectors in terms of performance [15] Industry Dynamics - The emotional value is driving consumer intentions, with a focus on "research-based consumption," "self-satisfaction," and "long-termism" as key decision-making trends [25][28] - High-end gold is becoming a preferred asset for wealth preservation, while fashion gold is appealing to younger consumers through innovative designs and social media engagement [32] - The cosmetics sector is witnessing a shift towards self-developed core ingredients and cultural narratives, enhancing brand value [37] Investment Recommendations - Focus on high-quality companies in the emotional consumption theme, particularly in the gold jewelry sector, with recommendations for brands like Chao Hong Ji and Lao Pu Gold [6][50] - Emphasize offline retail companies adapting to market changes, such as Yonghui Supermarket and Ai Ying Shi [6][48] - Highlight cosmetics brands that innovate in emotional value and safety, including Mao Ge Ping and Po Lai Ya [6][48] - Consider differentiated medical beauty product manufacturers and leading medical beauty institutions, recommending companies like Ai Mei Ke and Ke Di-B [6][48]

Group 1 - The core stock price of Runben Co., Ltd. (603193) closed at 24.47 yuan on December 26, 2025, down 1.96% from the previous week's closing price of 24.96 yuan [1] - The highest intraday price for Runben Co., Ltd. was 25.0 yuan on December 22, 2025, while the lowest was 24.2 yuan on December 24, 2025 [1] - The current total market capitalization of Runben Co., Ltd. is 9.803 billion yuan, ranking 3rd out of 12 in the personal care products sector and 1941st out of 5181 in the A-share market [1] Group 2 - Shenwan Hongyuan Securities conducted an on-site inspection of Runben Biotechnology Co., Ltd. for the year 2025, covering aspects such as corporate governance, information disclosure, and the use of raised funds [2] - The inspection confirmed that the corporate governance mechanism of Runben Co., Ltd. is operating effectively, with accurate and complete information disclosure and compliant use of raised funds [2][3] - During the inspection period, no related party fund occupation was found, and the company's operational status was reported as good with no significant changes in the business model [2][3]

Group 1 - The core point of the article highlights that Runben Co., Ltd. (603193) reported a closing price of 24.23 yuan as of December 31, 2025, with a market capitalization of 9.803 billion yuan, reflecting a slight increase of 0.12% from the previous trading day [1] - The stock opened at 24.2 yuan, reached a high of 24.45 yuan, and a low of 24.12 yuan, with a trading volume of 28.9473 million yuan and a turnover rate of 1.16% [1] - A recent inspection report by Shenwan Hongyuan Securities confirmed that the company's governance mechanisms are functioning effectively, with accurate and complete information disclosure, compliant use of raised funds, and no significant changes in its operating model [1][2] Group 2 - The inspection report indicated that there were no findings of related party fund occupation, and the company's operational status is reported as good [1] - The report also stated that there were no significant matters that needed to be reported to the China Securities Regulatory Commission and the stock exchange during the inspection period [1]

Market Overview - The personal care products sector increased by 0.23% on December 31, with Yanjiang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Yanjiang Co., Ltd. (300658) closed at 14.82, up 11.68% with a trading volume of 314,600 shares and a transaction value of 445 million yuan [1] - Other notable stocks include: - Dengkang Oral (001328) at 39.48, up 1.23% [1] - Zhongshun Jierou (002511) at 8.56, up 1.06% [1] - Beijia Clean (603059) at 30.08, up 0.37% [1] - Reliable Co., Ltd. (301009) at 12.68, up 0.32% [1] - Runben Co., Ltd. (603193) at 24.23, up 0.12% [1] - Haoyue Nursing (605009) at 30.90, up 0.03% [1] - Ziya Co., Ltd. (003006) at 21.84, down 0.46% [1] - Wanjian Medical (300888) at 37.84, down 0.58% [1] - Liangmian Needle (600249) at 5.75, down 1.71% [1] Capital Flow - The personal care products sector experienced a net outflow of 31.67 million yuan from institutional investors, while retail investors saw a net inflow of 26.33 million yuan [2] - The capital flow for individual stocks shows: - Yanjiang Co., Ltd. had a net inflow of 18.80 million yuan from institutional investors [3] - Dengkang Oral had a net inflow of 0.90 million yuan from retail investors [3] - Reliable Co., Ltd. had a net outflow of 3.37 million yuan from institutional investors [3] - Zhongshun Jierou had a net outflow of 7.21 million yuan from institutional investors [3] - Yiyi Co., Ltd. had a net outflow of 9.23 million yuan from institutional investors [3]

申万宏源证券承销保荐有限责任公司 关于润本生物技术股份有限公司 2025年度现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》、《上海证券交易所上市公 司自律监管指引第11号——持续督导》等有关法律法规的要求，申万宏源证券承销保 荐有限责任公司（以下简称"申万宏源承销保荐"或"保荐人"）作为润本生物技术股 份有限公司（以下简称"润本股份"或"公司"）首次公开发行股票并上市及持续督 导的保荐人，于2025年12月26日至12月29日对润本股份2025年度有关情况进行了现场 检查。 一、本次现场检查的基本情况 申万宏源承销保荐针对润本股份实际情况制订了2025年度现场检查工作计划。为 顺利实施本次现场工作，提高现场工作效率，切实履行持续督导工作，保荐人以邮件 方式将现场检查事宜通知润本股份，并要求公司提前准备现场检查工作所需的相关文 件和资料。2025年12月26日至12月29日，申万宏源承销保荐保荐代表人根据事先制订 的现场检查工作计划，采取与公司董事、高级管理人员及有关人员进行沟通和询问、 查看公司生产经营场所、查阅公司原始凭证及其他相关资料等形式，对包括公司治理 和内部控制情况、三会运作情况、信息 ...

Market Overview - The personal care products sector experienced a slight decline of 0.1% on December 30, with Liangmian Needle leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable stock performances in the personal care sector included: - Zhiya Co., Ltd. (003006) rose by 3.69% to close at 21.94, with a trading volume of 80,900 shares and a turnover of 178 million yuan [1] - Jieya Co., Ltd. (301108) increased by 1.04% to 33.86, with a trading volume of 10,700 shares and a turnover of 36.07 million yuan [1] - Liangmian Needle (600249) fell by 1.52% to 5.85, with a trading volume of 99,500 shares and a turnover of 58.49 million yuan [2] Capital Flow - The personal care products sector saw a net inflow of 23.84 million yuan from institutional investors, while retail investors experienced a net outflow of 48.31 million yuan [2] - The capital flow for individual stocks showed: - Yanjiang Co., Ltd. (300658) had a net inflow of 33.52 million yuan from institutional investors [3] - Liangmian Needle (600249) had a net outflow of 3.21 million yuan from institutional investors [3] Summary of Individual Stocks - The following stocks had significant capital movements: - Zhiya Co., Ltd. (003006) had a net inflow of 17.45 million yuan from institutional investors [3] - Jieya Co., Ltd. (301108) saw a net outflow of 0.87 million yuan from institutional investors [3] - Stable Medical (300888) had a net outflow of 3.61 million yuan from institutional investors [3]

Market Overview - The personal care products sector increased by 0.49% compared to the previous trading day, with Dengkang Oral leading the gains [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Stock Performance - Dengkang Oral (001328) closed at 38.95, up 2.04% with a trading volume of 19,000 shares and a transaction value of 73.72 million yuan [1] - Other notable performers include: - Yanjing Co. (300658) at 13.18, up 1.62% [1] - Stable Medical (300888) at 38.64, up 1.47% with a transaction value of 252 million yuan [1] - Zhongshun Jiesang (002511) at 8.45, up 1.32% with a transaction value of 191 million yuan [1] Capital Flow - The personal care products sector experienced a net outflow of 9.12 million yuan from institutional investors and 8.75 million yuan from retail investors, while retail investors saw a net inflow of 17.87 million yuan [2] - The capital flow for individual stocks shows: - Stable Medical had a net inflow of 18.89 million yuan from institutional investors [3] - Dengkang Oral saw a net outflow of 3.00 million yuan from institutional investors [3] - Yanjing Co. had a net inflow of 1.24 million yuan from institutional investors [3] Summary of Individual Stocks - The following stocks had significant capital movements: - Dengkang Oral: Institutional net outflow of 3.00 million yuan, retail net inflow of 0.80 million yuan [3] - Stable Medical: Institutional net inflow of 18.89 million yuan, retail net outflow of 20.84 million yuan [3] - Zhongshun Jiesang: Institutional net outflow of 3.24 million yuan, retail net inflow of 4.70 million yuan [3]

消费行业 2025 年总结与 2026 年展望 20251228 摘要 2025 年创新药 BD 爆发，前三季度出海金额达 920 亿美元，创销板块 表现突出，港股通创销板块涨幅高达 73%。预计 2026 年中国创新药将 通过 BD 方式更深入参与全球市场，推动生态体系变化。 2025 年 A 股社服零售板块表现偏后，但免税行业在 9 月已现复苏迹象。 展望 2026 年，服务消费负贝塔效应将减弱，政策倾斜预期增强，免税 和酒店估值修复，业绩兑现窗口或将到来。 2025 年第四季度家电行业处于消化期，国家补贴边际效应降低，出口 负增长。2026 年建议关注红利、全球化、AI 端侧应用和零部件跨界四 大领域，白电龙头红利价值较高，全球化关注关税影响。 2025 年轻纺行业内需承压，外贸受关税和汇率扰动，金饰表现亮眼。 2026 年仍需自下而上挖掘高景气成长股，优选具备竞争力的外贸品种， 关注金饰、服饰、制造业和个护等细分赛道。 2025 年农业牧渔行业机会偏小波段且结构性明显，生猪养殖板块占比 最大。预计 2026 年生猪产能去化将持续推动猪价上涨，建议重仓生猪 养殖主线，关注优质资产和弹性标的。 Q&A 2 ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry [2]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 1.1% from December 19 to December 26, 2025, which is weaker than the market performance [4][5]. - Lin Qingxuan is set to lead the high-end domestic essence oil sector with its upcoming IPO on December 30, 2025, planning to issue 13.9665 million H shares. The company has shown significant growth, with revenue projected to increase from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a compound annual growth rate (CAGR) of 32.7% [4][10]. - The report highlights the strong performance of Yiwang Yichuang (300792SZ) in the e-commerce agency sector, leveraging AI to enhance operational efficiency and revenue potential [11][12]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector's performance was weaker than the market, with specific indices showing declines: the Shenwan Cosmetics Index fell by 1.3%, and the Shenwan Personal Care Index decreased by 1.0% [4][5]. Key Company Developments - Lin Qingxuan's IPO is anticipated to bolster its market position, with a focus on high-end skincare products. The company has achieved a market share of 1.4% in the high-end skincare segment and ranks 10th in the anti-wrinkle product market with a 2.2% share [10]. - Yiwang Yichuang's business model is robust, with a comprehensive coverage of consumer goods categories and deep collaboration with Alibaba, positioning it well for future growth [11][12]. Market Trends - The report notes a recovery in the e-commerce agency sector, driven by increased demand for brand representation on platforms like Alibaba, with a notable rebound in traffic [12][13]. - The overall retail sales of cosmetics in China showed a growth of 4.8% year-on-year for the first 11 months of 2025, with November alone seeing a 6.1% increase, aided by promotional events [18][20]. Regulatory and Product Innovations - Jiangsu Chuangjian Medical Technology's collagen implant product received approval from NMPA, indicating ongoing innovation in the medical beauty sector [22]. - The report also mentions the investment by L'Oréal in a Chinese pharmaceutical company, marking a significant move into the skin health sector [25].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a transformation with a focus on emotional consumption and innovative product offerings, particularly in the jewelry and cosmetics sectors [6][33] - Companies like潮宏基 and毛戈平 are leveraging multi-channel strategies to enhance brand visibility and product sales, indicating a strong market presence [26][31] Summary by Sections Retail Market Overview - The retail index closed at 2462.73 points, with a weekly increase of 0.16%, underperforming the Shanghai Composite Index, which rose by 1.88% [5][15] - The retail sector has seen a year-to-date increase of 10.00%, lagging behind the Shanghai Composite Index's 18.26% rise [15][19] Company Highlights - **潮宏基**: Achieved a revenue of 62.37 billion yuan in the first three quarters of 2025, up 28.4% year-on-year, with a net profit of 3.17 billion yuan, reflecting a 0.3% increase [42] - **毛戈平**: Launched the "琉光赋活" skincare series, set to debut on January 1, 2026, focusing on high-end skincare needs [31] - **周大福**: Reported a revenue of 389.86 billion HKD for FY2026H1, a slight decrease of 1.1%, but with a net profit increase of 0.1% [39] Investment Themes - **Gold and Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending潮宏基 and老铺黄金 as key players [6][33] - **Offline Retail**: Emphasis on companies adapting to market changes, with recommendations for永辉超市 and爱婴室 [6][33] - **Cosmetics**: Highlighting brands that innovate with emotional value and safe ingredients, recommending毛戈平 and珀莱雅 [6][34] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical aesthetic chains, with recommendations for爱美客 and科笛-B [6][34]